Raymond Limited Reports Robust Q3 FY26 Performance with 18% Revenue Growth

Raymond Limited announced strong unaudited financial results for Q3 FY26. Total Income increased to ₹580 Cr, up 18% Y-o-Y. EBITDA reached ₹83 Cr, a 27% Y-o-Y increase, with an improved EBITDA margin of 14.3%. The company remains net debt-free with a net cash surplus of ₹214 Cr. Both Aerospace & Defense and Precision Technology segments drove growth.

Key Financial Highlights

Raymond Limited showcased a strong financial performance for Q3 FY26, driven by key business segments:

  • Total Income: Increased by 18% year-over-year, reaching ₹580 Cr compared to ₹493 Cr in Q3 FY25.
  • EBITDA: Rose to ₹83 Cr, marking a 27% increase from ₹65 Cr in Q3 FY25.
  • EBITDA Margin: Improved to 14.3%, an increase of approximately 100 bps from 13.3% in Q3 FY25.
  • Debt Status: Remains net debt-free with a net cash surplus of ₹214 Cr.

Segment Performance

The company’s growth was significantly propelled by the Aerospace & Defense and Precision Technology & Auto Components segments. Key details include:

Precision Technology & Auto Components

  • Revenue: ₹417 Cr, up 15% Y-o-Y
  • EBITDA: ₹57 Cr, up 51% Y-o-Y
  • EBITDA Margin: 13.7%

Aerospace & Defense

  • Revenue: ₹105 Cr, up 49% Y-o-Y
  • EBITDA: ₹19 Cr, up 39% Y-o-Y
  • EBITDA Margin: 18.6%

Operational Developments

Raymond Limited is witnessing a trend of domestic vendors transitioning to produce sophisticated subsystems and complex precision components. This ensures a robust order pipeline for Tier-1 and Tier-2 export partners. While operational performance remains strong, EBITDA margins faced temporary pressure due to a reduction in non-operating income.

Source: BSE

Previous Article

ISGEC Heavy Engineering Board Meeting Scheduled for February 9, 2026

Next Article

Alembic Pharmaceuticals Receives USFDA Final Approval for Difluprednate Ophthalmic Emulsion